Matarajio ya kansa ya tezi-kibofu hutegemea mambo kadhaa, kutia ndani hatua ya kansa, umri wa mgonjwa na afya yake kwa ujumla, na jinsi chembe za kansa zilivyo hatari.
Kwa ujumla, kansa ya tezi-kibofu ina matarajio mazuri, hasa inapogunduliwa mapema.
Kiwango cha kuishi kwa miaka mitano kwa kansa ya tezi-kibofu (kansa ambayo haijaenea zaidi ya tezi-kibofu) ni karibu 100%. Hata hivyo, utabiri unazidi kuwa mbaya kadiri kansa inavyoendelea na kuenea kwenye sehemu nyingine za mwili.
Ni muhimu kujadili utabiri hususa na mtaalamu wa huduma ya afya, kwa kuwa unaweza kutofautiana sana kutoka mtu mmoja hadi mwingine.
Yang X, Wang R, Xu K, Yang F, Chen Y, Zuo Z, Song B: [Knockdown of myeloid cell leukemia 1 gene inhibits the proliferation and promotes apoptosis of prostate cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017, 33 (1): 62-66.
Kubota Y, Ito K, Imai K, Yamanaka H: Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate. 2002, 50 (4): 262-9.
Li K, Zhou H, Wang F, Zhao C, Fan C, Wang J: ZBTB38 suppresses prostate cancer cell proliferation and migration via directly promoting DKK1 expression. Cell Death Dis. 2021, 12 (11): 998.
Sun HF, Wang WD, Feng L: Effect of SPAG9 on migration, invasion and prognosis of prostate cancer. Int J Clin Exp Pathol. 2017, 10 (9): 9468-9474.
Xia Q, Li J, Yang Z, Zhang D, Tian J, Gu B: Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Medicine (Baltimore). 2020, 99 (7): e18993.
Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y, Zhang T, Zhou J, Wang P: TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol. 2019, 121 (): 200-206.
Rucci N, Angelucci A: Prostate cancer and bone: the elective affinities. Biomed Res Int. 2014, 2014 (): 167035.
Kanusho la dhima: matibabu
Tovuti hii hutolewa kwa madhumuni ya elimu na habari tu na si kutoa ushauri wa matibabu au huduma za kitaaluma.
Habari inayotolewa haipaswi kutumiwa kugundua au kutibu tatizo la afya au ugonjwa, na wale wanaotafuta ushauri wa kibinafsi wa kitiba wanapaswa kushauriana na daktari aliye na leseni.
Tafadhali kumbuka mtandao wa neva ambao hutengeneza majibu ya maswali, ni hasa usio sahihi linapokuja maudhui ya nambari. Kwa mfano, idadi ya watu waliogunduliwa na ugonjwa fulani.
Daima kutafuta ushauri wa daktari wako au mtoa huduma nyingine ya afya waliohitimu kuhusu hali ya matibabu. Kamwe kupuuza ushauri wa matibabu ya kitaaluma au kuchelewesha katika kutafuta yake kwa sababu ya kitu umesoma kwenye tovuti hii. Kama unafikiri unaweza kuwa na dharura ya matibabu, piga simu 911 au kwenda chumba cha dharura karibu mara moja. Hakuna uhusiano daktari-mgonjwa ni kuundwa na tovuti hii au matumizi yake. Wala BioMedLib wala wafanyakazi wake, wala mchangiaji yoyote ya tovuti hii, hufanya uwakilishi wowote, wazi au implicit, kuhusiana na taarifa zinazotolewa hapa au matumizi yake.
Utoaji wa dhima: hakimiliki
The Digital Millennium Copyright Act ya 1998, 17 U.S.C. § 512 (the DMCA) hutoa njia ya kurudi kwa wamiliki wa hakimiliki ambao wanaamini kuwa vifaa vinavyoonekana kwenye Mtandao vinakiuka haki zao chini ya sheria ya hakimiliki ya Merika.
Kama unaamini kwa imani nzuri kwamba maudhui yoyote au nyenzo zilizotolewa kuhusiana na tovuti yetu au huduma inakiuka hakimiliki yako, wewe (au wakala wako) unaweza kutuma sisi taarifa kuomba kwamba maudhui au nyenzo kuondolewa, au upatikanaji wake kuzuiwa.
Taarifa lazima zipelekwe kwa maandishi kwa barua pepe (tazama sehemu ya "Contact" kwa anwani ya barua pepe).
DMCA inahitaji kwamba taarifa yako ya madai ya ukiukaji wa hakimiliki ni pamoja na taarifa zifuatazo: (1) maelezo ya kazi ya hakimiliki ambayo ni madai ya ukiukaji; (2) maelezo ya madai ya ukiukaji maudhui na habari ya kutosha kuruhusu sisi kupata maudhui; (3) mawasiliano ya habari kwa ajili yenu, ikiwa ni pamoja na anwani yako, nambari ya simu na anwani ya barua pepe; (4) taarifa na wewe kuwa na imani nzuri imani kwamba maudhui katika njia alilalamika ya si mamlaka na mmiliki wa hakimiliki, au wakala wake, au na operesheni ya sheria yoyote;
(5) taarifa na wewe, saini chini ya adhabu ya ushahidi wa uongo, kwamba habari katika taarifa ni sahihi na kwamba una mamlaka ya kutekeleza haki za hakimiliki ambayo ni madai ya kukiuka;
na (6) saini ya kimwili au ya elektroniki ya mmiliki wa hakimiliki au mtu aliyeidhinishwa kutenda kwa niaba ya mmiliki wa hakimiliki.
Kushindwa kujumuisha habari zote hapo juu kunaweza kusababisha ucheleweshaji wa usindikaji wa malalamiko yako.
Mawasiliano
Tafadhali tutumie barua pepe na swali lolote / pendekezo.
What is prognosis of prostate cancer?
The prognosis of prostate cancer depends on several factors, including the stage of the cancer, the patient's age and overall health, and the aggressiveness of the cancer cells.
In general, prostate cancer has a good prognosis, especially when caught early.
The 5-year survival rate for localized prostate cancer (cancer that has not spread beyond the prostate) is nearly 100%. However, the prognosis worsens as the cancer progresses and spreads to other parts of the body.
It is important to discuss the specific prognosis with a healthcare professional, as it can vary greatly from person to person.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Karibu
BioMedLib hutumia kompyuta za kiotomatiki (algorithms ya kujifunza mashine) kuzalisha jozi za maswali na majibu.
Tunaanza na machapisho milioni 35 ya biomedical ya PubMed/Medline. Pia, kurasa za wavuti za RefinedWeb.
